Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study
Daphne T Adelman,1 Andrea Burgess,2 Philippa R Davies,31Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; 2Neuroendocrine Tumor Department, The Christie, Manchester, UK; 3Neuroendocrine Tumor Unit, Royal Free Hospital, London, UKAbstract: The somatostatin analogs (SSAs) lanreot...
Guardado en:
Autores principales: | Adelman DT, Burgess A, Davies PR |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9ecc58596e764d0f83610329d0c37beb |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Decision-tree model for health economic comparison of two long-acting somatostatin receptor ligand devices in France, Germany, and the UK
por: Marty R, et al.
Publicado: (2012) -
Evaluation of the impact of viscosity, injection volume, and injection flow rate on subcutaneous injection tolerance
por: Berteau C, et al.
Publicado: (2015) -
Usability of devices for self-injection: results of a formative study on a new disposable pen injector
por: Lange J, et al.
Publicado: (2014) -
ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study
por: Boeru G, et al.
Publicado: (2013) -
Acceptability of the reusable SurePal™ self-injection device for Omnitrope® among pediatric patients: results from a questionnaire-based, cross-sectional, multicenter observational study
por: Partsch CJ, et al.
Publicado: (2015)